Alex Titomirov (born January 30, 1960) is an Russian-American businessman, and the co-founder and Chairman of GenforMax LLC. Alex previously served as CEO and Chairman of InforMax Inc and is also a founder of several other companies.

Top

Summary

A successful biotech CEO, Alex Titomirov founded one of the first bioinformatics companies - InforMax [NASDAQ, INMX] and brought it public ($1 billion market cap) with “the best biotech IPO” [Washington Post, 2000 in the State of Maryland]. InforMax IPO in October 2000 was a record success with x20 times "over-the-book" orders for the company's stock; with 5M shares sold - orders for 100M shares were received. Dr. Titomirov has produced such huge interest in his company within 3 weeks of the IPO road show performing 100 presentations in about 20 cities worldwide. He and his team are ready to do it again with his new company GenforMax. The optimum global analysis would be performed on where and when to list the company once it is ready for that. While some markets seems to be hard hit by the crisis, others seems like are available for companies with great vision and technology.

Titomirov was a founder of several pioneering technologies in the field of cancer treatment at the Russian Academy of Sciences. He discovered a bacterial DHFR genetic effect that prolonged the lifespan in irradiated mice, and he was one of the original authors of stable gene transformation of skin cells in vivo using the pioneering technology of “shot gun” with tungsten micro projectiles. Titomirov was invited to come to work in the United States by James Watson – a Nobel Prize winner and a pioneer in discovering the structure of DNA. He worked at the National Institutes of Health as well as in a small pharmaceutical company before starting his own company InforMax, Inc. in 1990. Titomirov has pioneered an expert system based on modeling of the drug discovery process. InforMax products are currently sold to over 65,000 pharma and biotech companies worldwide. InforMax was acquired by Invitrogen, a major bioscience company with $1.2 billion in annual revenues, headquartered in Carlsbad, California. In addition, Titomirov was one of the principal developers of the software infrastructure for the Human Genome Project, founded by James Watson. Titomirov was a major contributor to the Genomics Approach of drug discovery – which is demonstrated to be one of the main accelerators of drug discovery process. Titomirov earned his Ph.D. in 1986 at the Institute of Cytology at the Russian Academy of Sciences in St. Petersburg, Russia. Dr. Titomirov pioneered the field of transforming animal cells with foreign DNA which had led to development of human DNA vaccines and was a major contribution to human genetics

Top

Professional History

GenforMax LLC

Dr. Titomirov is currently building GenforMax corporation dedicated to bringing DNA and RNA interpretation tools to the market of popular as well as professional DNA analysis. The company plans to provide the necessary DNA/RNA analysis tools to professionals (biotech and pharma companies) as well as to hospitals and private individuals.

SanteFutur SARL

Dr. Alex Titomirov is a Founder, Chairman. The Supplement company specializing in polyphenols extractions of different berries which are very helpful in preventing cancer and other metabolic disorders. Dr. Titomirov financed 100% of company development.

Real Time Health Corporation

Dr. Alex Titomirov - Founder, Chairman and CEO: The preventive medicine company specializing in developing devices for measuring the concentration of different metabolites in the human body including PSA, insulin etc.

Stemron Corporation

Dr. Alex Titomirov - Co-Founder and Chairman. A Stem Cell company with the mission of developing the non-embryonic stem cells for organ transplantation.

The Royall Titomirov Group Corporation

Dr. Alex Titomirov - Founder, Chairman. Merchant bank specializing in M&A and LBOs.

InforMax Inc

CEO/Chairman of the Board, InforMax, Inc. Company went public with the peak value of 1 billion USD (NASDAQ: INMX); InforMax was sold to Invitrogen in November, 2002. InforMax has successfully developed the biological software packages - Vector NTI and GenoMax which went through extensive evaluation and testing at different sites worldwide. InforMax had customers in 50 countries worldwide with the group of users over 65,000 researchers in thousands of companies and universities. InforMax Inc. was also assisting The National Center for Biotechnology Information (NCBI, NIH) with various programs including but not limited to the Human Genome Project, GenBank, Entrez, PubMed, and MedLine.

Top

Bibliography (Selected Publications)

  • Glebov, O.K., Titomirov, A.V., Pinaev, G.P., and Tomilin, N.V. Transformation of Chinese hamster cell by the plasmid pBR325::HS3::TK and the influence of TPA on stability of transformants (1982) Proc. Natl. Acad. Sci. of the USSR (Dokl. AN USSR, transl.) 267: 1496-1498
  • Titomirov, A.V., Pereversev, A.E., Stepanian, L.I., Podgornaya, O.I., and Aprelikova, O.N. Transfection of bone marrow colony forming cells of mouse by the plasmid containing bacterial dihydrofolate reductase (DHFR) gene (1985) Cytology (Tsitologiya, Rus.) 27: 1183-1188.
  • Titomirov, A.V., Aprelikova, O.N., Vaisman, B.L., and Tomilin, N.V. Transgenic mice containing procaryotic DHFR gene (1985) Cytology (Tsitologiya, Rus.) 27: 1374-1379.
  • Pereversev, A.E., Titomirov, A.V., Stepanian, L.I., Podgornaya, O.I., and Aprelikova, O.N. Selection in vivo of colony forming cells transformed by bacterial DHFR gene (1986) Proc. Natl. Acad. Sci. USSR (Dokl. AN USSR, transl.) 288: 233-236.
  • Tomilin, N.V., Titomirov, A.V., and Stepanian, L.I. Transformation of teratocarcinoma cells CBA 9H6 by bacterial DHFR gene (1987) Cytology (Tsitologiya, Rus.) 29:1385-1391.
  • Titomirov, A.V., and Zelenin, A.V. New methods of transfection of mammalian cells: A Minireview (1988) Molecular Biology (Moscow, transl.) 22: 1445-1450.
  • Zelenin, A.V., Titomirov, A.V., and Kolesnikov, V.A. Genetic transformation of mouse cultured cells with the help of high velocity mechanical DNA injection (1989) FEBS Letters 244: 65-67.
  • Titomirov, A.V., Sukharev, S.N., and Kistanova, E. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA (1990) Biochemica et Biophysica Acta, 1088: 131-134.
  • Zelenin, A.V., Alimov, A.A., Titomirov, A.V. et al. High- velocity mechanical DNA transfer of chloramphenicol acetyl transferase gene into rodent liver, kidney and mammalian gland cells in organ explants and in vivo (1991) FEBS Lett. 280:94-96.
  • Sukharev, S.S., Titomirov, A.V., and Klenchin, V.A. Electrically-Induced DNA Transfer Into cells. (1994 Birkhauser, Boston) Jon A. Wolff Editor. Pp 210-232.

Top